Cytotoxic and antiproliferative activity of Securidaca longepedunculata aqueous extract on Ehrlich ascites carcinoma cells in Swiss albino mice (original) (raw)
Related papers
Endocrine Related Cancer, 2005
This study was designed to address whether simultaneous primary chemo-hormonal therapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2-4, N0-1, M0 breast cancer were randomized to receive either epirubicin alone (EPI) or epirubicin plus tamoxifen (EPI-TAM). Ki67 expression was evaluated immunohistochemically in tumor specimens obtained before chemotherapy by incision biopsy and at definitive surgery. Tumor shrinkage of >50% was obtained in 76% of patients randomized in the EPI arm and 81.9% of patients randomized in the EPI-TAM arm (not significant). The corresponding rates of clinical and pathological complete response were 20.2 and 21.9% (not significant), and 4.8 and 6.7% (not significant), respectively. Pathologically complete response was more frequently observed in estrogen receptor (ER)-negative (ER -) tumors (P=0.04) and correlated with elevated baseline Ki67 expression (P<0.01). Both EPI and EPI-TAM treatments resulted in a significant reduction in Ki67 expression, either in overall patients (P=0.000) or in patients with ER+ breast cancer (P=0.000). The reduction in Ki67 immunostaining in the EPI-TAM arm was greater than in the EPI arm, leading to a lower Ki67 expression at post-operative residual histology (P=0.0041). The addition of tamoxifen to epirubicin chemotherapy did not improve the response rate but led to a significantly higher reduction in the Ki67 expression. Baseline elevated Ki67 expression and the ERstatus were both associated with a greater chance of obtaining a pathological complete response at residual histology.
British journal of cancer, 2001
The association between tumour shrinkage and reduction in kinetic cell activity after primary chemotherapy in human breast cancer is still a matter of investigation. 157 patients with T2-4, N0-1, M0 breast cancer received primary chemotherapy consisting of either the CMF regimen + tamoxifen (the first consecutive 76 cases) or the single agent epirubicin (the subsequent 81). Ki67, p53, bcl2, c-erbB2 and steroid hormone receptors were evaluated immunohistochemically in tumour specimens obtained before chemotherapy and at surgery. Tumour shrinkage of >50% occurred in 72.4% of patients. Ki67 expression significantly decreased after chemotherapy; the reduction correlated with tumour response in both univariate (P < 0.005) and multivariate analysis (P = 0.02). p53, bcl-2, steroid hormone receptor and c-erbB2 immunostaining were scarcely affected. Baseline bcl2 (P = 0.04) and c-erbB2 (P = 0.02) were directly and inversely associated with the reduction in Ki67 immunostaining, respecti...
JNCI Journal of the National Cancer Institute, 2007
Tumor expression of the proliferation antigen Ki67 is widely used to assess the prognosis of cancer patients. A change in the expression of Ki67 after short-term exposure of patients to therapeutic agents is frequently used as a pharmacodynamic marker of efficacy, particularly among breast cancer patients before undergoing surgery. To determine the clinical significance of the level of tumor cell proliferation during endocrine therapy for breast cancer, we measured the expression of Ki67 in tumor biopsy samples taken before and after 2 weeks of presurgical treatment with anastrozole or tamoxifen or the combination of anastrozole plus tamoxifen in 158 patients with hormone receptor-positive primary disease. In a multivariable analysis, we found that higher Ki67 expression after 2 weeks of endocrine therapy was statistically significantly associated with lower recurrence-free survival (P = .004) whereas higher Ki67 expression at baseline was not. Larger baseline tumor size and lower estrogen receptor level after 2 weeks of treatment were also statistically significantly associated with poorer recurrence-free survival (P<.001 and P = .04, respectively). Our data indicate that measurements of tumor Ki67 level after short-term endocrine treatment may improve the prediction of recurrence-free survival by integrating the prognostic value of Ki67 level at baseline with changes in Ki67 level that are associated with treatment benefit.
Annals of Oncology, 2011
Craniopharyngiomas are histological benign tumors. Craniopharyngiomas are slowly growing locally invasive intracranial tumors that can generate considerable morbidity and recurrences that are often difficult to manage. Reliable morphologic criteria for predicting clinical outcome of these tumors are lacking. The aim of the study was to investigate the prognostic value of Ki-67 labeling indices and p53 protein expression for recurrence in craniopharyngiomas. A series of 47 patients with craniopharyngiomas (29 male and 18 female; age range:4-74 years, mean years:31.4±17.8) were reviewed. Nine cases were papillary squamous and 38 cases were adamantinomatous variant. Tumors recurred in 10 (%21.2) patients (range 2-120, mean 23.2 months). Ki-67 labeling indices varied from 0 % to 12 % (mean 1.68±2.7 %). The ratio of p53 staining was 1-25% in 24 cases, in most majority (17 cases) it was under 10%. Ki-67 labeling index and p53 immunopositivity showed no statistically significant correlation with tumor recurrences and histological subtypes. Low Ki-67 labeling indices and p53 immunopositivity are common findings in the majority of craniopharyngiomas. Ki-67 labeling indices and p53 expression of primary tumors did not have prognostic value to predict tumor recurrence.
innovative publication, 2017
Background: One of the most common causes of carcinoma deaths among women is breast cancer. In view of the above, early diagnosis and effective treatment of the disease are immensely important. The increasing number of options for the treatment of breast cancer has made the prognostic evaluation of the disease even more important. Proliferation plays an important role in the clinical behaviour of invasive breast cancer. Ki 67 binding, is an objective measurement of cell proliferation which significantly aids in the management of the breast cancer patients. Objectives: 1. To study the proliferative activity using Ki 67 immunostaining in breast carcinoma. 2. To assess the relationship of Ki 67 scores with size, histological grade and lymph node status. Methods: Seventy five cases of histologically proven breast carcinomas were studied. Histopathological grade was assessed using Bloom and Richardson's method, modified by Elston and Ellis. Immunohistochemistry (IHC) for Ki 67 was done on paraffin embedded wax sections. Results: Ki 67 was positive in 73/75 cases (97.33%). The range of Ki 67 score was 0 to 90%. Mean value of Ki 67 was 31.86% and median was 30%. A statistically significant correlation was observed between size (P=0.037), grade (P < 0.0001) and Nottingham Prognostic Index (P < 0.0001) with Ki 67 scores. No statistically significant correlation was seen with lymph node status (P=0.767), lymphovascular invasion, necrosis, presence of desmoplasia, ductal carcinoma in situ (DCIS), nipple and areola involvement. Conclusion: Proliferation has been recognized as a distinct hallmark of cancer and acts as an important determinant of cancer outcome. As Ki 67 can be used to objectively measure this, it can be included in the pool of prognostic markers like tumor size, nodal status, histopathological grade and hormonal receptors.
Iranian journal of pathology, 2018
Breast cancer is the most common malignancy among women. The Neoadjuvant chemotherapy is the treatment of choice for non-operable tumors. The Ki67 is a proliferation marker that can be used to predict the therapeutic response to chemotherapy and the patients' prognosis. This retrospective study was carried out on 55 consecutive patients with breast cancer referred to a Training Tertiary Healthcare Center in Kerman, Iran since 2009 to 2014. After diagnostic approval, the tissue samples of patients were examined for estrogen and progesterone receptors, ki67 and HER2-neu markers by using immunohistochemical staining. Then the patients were treated with 6 cycles of Neoadjuvant chemotherapy regimens by Doxorubicin and Taxans or 4 chemotherapy cycles, containing Anthracycline and Cyclophosphamide and 4 cycles of Paclitaxel. After mastectomy, their samples were reexamined for ki67 again and classified into three groups (low: ki67<15%), medium (Ki67 = 16-30%) and high (Ki67> 30%)....
Journal of Pharmaceutical Research International, 2021
Background: Breast carcinoma is the second most frequently occurring malignant tumor. It usually arises in a multistep fashion from intermediary lesions to invasive cancer. Identifying such predominantly occurring lesions adjacent to malignancy and studying of Proliferative Ki-67 index and (ER) status in such lesions and substantiate their possible identity as a premalignant lesion. The study tries to establish the lesions which have the potential for progression to overt malignancy, thereby indicating early identification and appropriate treatment. Aim: To establish a correlation in the expression of Ki-67 proliferative index in the peritumoral tissue with tumor mass of ER-positive breast carcinomas. Objectives: 1.To study the expression of ER in breast tumor mass. 2. To study expression of Ki-67 proliferative index in breast tumor mass and peritumoral tissue. 3. To assess the expression of Ki-67 proliferative index in breast tumor mass and peritumoral tissue. Study design: Observa...
British journal of cancer, 1993
This study aimed to investigate the effect of tamoxifen on breast tumour levels of oestrogen and progesterone receptor (ER and PR) and proliferation as defined by the Ki67 antibody. A group of primary breast cancer patients was randomised to receive either tamoxifen (n = 59) or placebo (n = 44) treatment in the interval between clinic and surgery (median 21 days). Frozen sections of breast tumour biopsies obtained before and after treatment were stained immunocytochemically to obtain the percentage of nuclei containing ER and PR, and a Ki67 labelling index (LI). Tamoxifen-treated patients had a median Ki67 LI of 5.6% in the first biopsy falling to 3.0% in the second biopsy (P < 0.001 by Wilcoxon's matched pairs test), whereas placebo-treated patients had a median Ki67 LI of 5.4% in the first biopsy and 5.75% in the second (no significant difference). No significant differences were observed when the median %ER or %PR staining before and after treatment were compared. The Ki67...
Cancer Chemotherapy and Pharmacology, 2019
Purpose Many studies have indicated that the response to therapy and the prognostic impact of a pathologic complete response after neoadjuvant treatment differ among breast cancer subtypes. Methods The aim of our study is to evaluate the effect of this treatment on the expression of estrogen and progesterone receptors, human epidermal growth hormone receptor 2 and Ki67 in breast cancer. We identified 125 patients. Results The estrogen receptor modified its expression from positive to negative in 8% patients and from negative to positive in 22%; progesterone in 21% and in 37% cases. Median Ki-67 value was 20.9% at biopsy and 18% after, HER-2 status did not show a remarkable change before or after neoadjuvant chemotherapy (NACT). We have identified a significant reduction in Ki-67 expression levels after chemotherapy in patients with a pathologic response. Detection of pretreatment Ki-67 could identify patients most likely to benefit from NACT. Conclusions NACT can change the status of ER, PgR, and Ki-67 expression in patients with breast adenocarcinoma, but it did not exert a significant effect on HER-2 status; HER-2 amplification appears to be more stable. We have identified a prognostic role for a decreased expression of PgR and Ki-67 after preoperative chemotherapy in breast cancer patients.
Prognostic role of Ki67 determined on metastatic tissue of patients with advanced breast cancer
The Breast, 2011
The purpose of this study is to determine the prognostic role of Ki67 evaluated in relapse biopsies from patients with metastatic breast cancer (MBC). Two hundred and ten patients diagnosed with MBC in Stockholm, Sweden between 1998 and 2009 and with Ki67 assessed at time of first systemic relapse (mKi67) were retrospectively identified and divided into two groups according to mKi67 fraction (low B20 %, high [20 %). Post-relapse survival was compared between the groups using Kaplan-Meier and Cox regression methods. Death rate as function of continuous mKi67 was also evaluated. Furthermore, the prognostic role of intra-individual change in Ki67 between primary tumor and matched metastasis was explored by Kaplan-Meier plots. One hundred and twenty-five patients had low and 85 had high mKi67. Median survival was 25 and 17 months in low-and high-mKi67 group, respectively [hazard ratio (HR) 0.69, 95 % confidence intervals (CI) 0.51-0.92, P = 0.01]. In a multivariate model adjusted for prognostic confounders, low-mKi67 showed a non-significant trend toward better survival (HR 0.85, 95 %CI 0.62-1.16, P = 0.30). Nevertheless, mKi67 independently correlated with survival when compared with primary tumor proliferation (HR 0.56, 95 %CI 0.38-0.81, P = 0.002). The 2-year death rate steeply increased as mKi67 increased. Moreover, the change from high in primary tumor to low in metastasis significantly correlated with longer survival when compared with stable Ki67 levels (HR 0.48, 95 %CI 0.31-0.76, P = 0.002). In this cohort of MBC patients, mKi67 inversely but not independently correlated with survival. However, a significant association between mKi67 and survival was shown regardless of primary tumor proliferation. Keywords Metastatic breast cancer Á Prognosis Á Proliferation Á Ki67 Á Relapse biopsy Abbreviations CI Confidence intervals EBC Early breast cancer ER Estrogen receptor FNAC Fine-needle aspiration cytology HER2 Human epidermal growth factor receptor 2 HR Hazard ratio MBC Metastatic breast cancer mKi67 Ki67 measured in metastasis OS Overall survival pKi67 Ki67 measured in primary tumor PR Progesterone receptor RFI Recurrence-free interval TMAs Tissue microarray sections Electronic supplementary material The online version of this article (